Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003

Página do item simplificado
dc.contributor.authorMatta, Daniel Archimedes da [UNIFESP]
dc.contributor.authorAlmeida, Leila Paula de
dc.contributor.authorMachado, Antonia Maria
dc.contributor.authorAzevedo, Ana Carolina
dc.contributor.authorUra Kusano, Elisa Junko
dc.contributor.authorTravassos, Norma Fracalanza
dc.contributor.authorSalomão, Reinaldo [UNIFESP]
dc.contributor.authorColombo, Arnaldo Lopes
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHosp Serv Publ Estadual São Paulo
dc.date.accessioned2016-01-24T12:42:01Z
dc.date.available2016-01-24T12:42:01Z
dc.date.issued2007-04-01
dc.description.abstractWe evaluated all Candida sp. bloodstream isolates obtained from patients admitted to 4 tertiary care hospitals between 1995 and 2003 in the city of São Paulo, Brazil. Susceptibility to amphotericin B, 5-fluorocytosine, fluconazole (FCZ), itraconazole (ITZ), and voriconazole (VCZ) was determined using the Clinical Laboratory Standards Institute broth microdilution method. We tested a total of 1000 strains, including 400 strains of Candida albicans (40%), 243 of Candida tropicalis (24.3%), 238 of Candida parapsilosis (23.8%), 44 of C. glabrata (4.4%), 30 of Candida guillierniondii (3%), and 25 of Candida rugosa (2.5%). Only 1.9% of the strains tested were susceptible in a dose-dependent manner, and 0.2% of them were resistant to FCZ. Almost 100% of the strains were susceptible to VCZ. Despite that azole resistance was a rare finding, a trend toward increased resistance among C. rugosa strains to FCZ and ITZ was noted. (c) 2007 Elsevier Inc. All rights reserved.en
dc.description.affiliationUniversidade Federal de São Paulo, Div Infect Dis, BR-04023062 São Paulo, Brazil
dc.description.affiliationHosp Serv Publ Estadual São Paulo, Microbiol Sect, BR-04038034 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Infect Dis, BR-04023062 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent399-404
dc.identifierhttp://dx.doi.org/10.1016/j.diagmicrobio.2006.10.011
dc.identifier.citationDiagnostic Microbiology and Infectious Disease. New York: Elsevier B.V., v. 57, n. 4, p. 399-404, 2007.
dc.identifier.doi10.1016/j.diagmicrobio.2006.10.011
dc.identifier.issn0732-8893
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29625
dc.identifier.wosWOS:000245698700008
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofDiagnostic Microbiology and Infectious Disease
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectCandida sppen
dc.subjectcandidemiaen
dc.subjectantifugal susceptibility testingen
dc.subjectresistanceen
dc.titleAntifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003en
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral